Published in Ann Hematol on October 01, 2000
Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol (2002) 0.97
Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis (2007) 0.97
Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma (2011) 0.97
Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. J Oncol (2010) 0.94
Clinical trials with anti-angiogenic agents in hematological malignancies. J Angiogenes Res (2010) 0.90
Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol (2008) 0.89
The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol (2004) 0.87
Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer (2002) 0.87
Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. Am J Pathol (2004) 0.85
Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol (2003) 0.85
Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance. ScientificWorldJournal (2012) 0.81
Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma. Med Sci Monit (2013) 0.79
BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma. Ann Hematol (2013) 0.79
Prognostic impact of angiopoietin-2 in multiple myeloma. J Cancer Res Clin Oncol (2014) 0.77
Whole body MRI and PET/CT in haematological malignancies. Cancer Imaging (2007) 0.76
Adverse prognostic impact of bone marrow microvessel density in multiple myeloma. Ann Lab Med (2015) 0.76
Expression of C-Reactive Protein in Rectal Cancer. Gastroenterology Res (2009) 0.75
Plasma Levels of Monocyte Chemotactic Protein-1 Are Associated with Clinical Features and Angiogenesis in Patients with Multiple Myeloma. Biomed Res Int (2016) 0.75
Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. Leuk Lymphoma (2013) 0.75
Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma. Skeletal Radiol (2017) 0.75
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 4.16
Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med (1997) 2.88
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer (2008) 2.67
ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol (2004) 2.45
Acute right-sided heart failure due to hemorrhage into a pericardial cyst. Ann Thorac Surg (1997) 2.24
European and US publications in the 50 highest ranking pathology journals from 2000 to 2006. J Clin Pathol (2007) 2.20
Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest (1996) 2.00
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res (1997) 1.89
Contaminations occurring in fungal PCR assays. J Clin Microbiol (1999) 1.86
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology (2000) 1.82
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell (2000) 1.70
Mucormycoses. Mycoses (2001) 1.70
Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol (2001) 1.67
Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer (2000) 1.65
Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer (2005) 1.65
Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis (1989) 1.64
Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol (2001) 1.62
Subcutaneous crystal-storing histiocytosis associated with lymphoplasmacytic lymphoma (immunocytoma) Pathol Res Pract (1996) 1.57
CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer (2003) 1.49
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst (1999) 1.46
Quality indicators in breast cancer care. Eur J Cancer (2010) 1.46
Telemicroscopy via the internet. Nature (1998) 1.44
Small-cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 10q, 13q and 17p. Br J Cancer (1997) 1.44
Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol (2001) 1.43
[Inter-disciplinary European guidelines on surgery of severe obesity]. Vnitr Lek (2008) 1.42
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer (2008) 1.41
Diagnosis and treatment of AL amyloidosis. Clin Nephrol (2000) 1.40
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer (2004) 1.39
Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol (1995) 1.39
PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat (2003) 1.39
Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer (2000) 1.38
High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer (2007) 1.37
Second consensus on medical treatment of metastatic breast cancer. Ann Oncol (2006) 1.37
Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology (2000) 1.36
Preliminary study on administration of high-titer lipid A antibody serum in sepsis and septic shock patients. Infection (1985) 1.35
Spectrum of congenital heart defects and extracardiac malformations associated with chromosomal abnormalities: results of a seven year necropsy study. Heart (1999) 1.33
Bortezomib inhibits human osteoclastogenesis. Leukemia (2007) 1.30
Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 1.30
Expression of AGR2 in non small cell lung cancer. Histol Histopathol (2007) 1.26
Functional identification of the glycerol permease activity of Arabidopsis thaliana NLM1 and NLM2 proteins by heterologous expression in Saccharomyces cerevisiae. FEBS Lett (2000) 1.24
Prognostic factors for adenoid cystic carcinoma of the head and neck: a retrospective evaluation of 96 cases. J Oral Pathol Med (1990) 1.20
Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res (2001) 1.19
Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol (2000) 1.17
Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol (2006) 1.17
Genomic alterations associated with malignancy in head and neck cancer. Head Neck (1998) 1.17
A haemorrhagic fever from the Côte d'Ivoire. Lancet (1999) 1.17
Size 2 ProSeal laryngeal mask airway: a randomized, crossover investigation with the standard laryngeal mask airway in paediatric patients. Br J Anaesth (2004) 1.16
Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology (1996) 1.16
Primary small-cell lung carcinomas and their metastases are characterized by a recurrent pattern of genetic alterations. Int J Cancer (1997) 1.16
Distinct patterns of chromosomal alterations in high- and low-grade head and neck squamous cell carcinomas. Cancer Res (1996) 1.14
[Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. Pathologe (2010) 1.14
Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis (2000) 1.14
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol (1998) 1.14
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol (2014) 1.13
International terminology of colposcopy: an updated report from the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol (2003) 1.13
The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene (2006) 1.13
Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate (2000) 1.12
Orbital metastases in breast cancer: report of two cases and review of the literature. J Cancer Res Clin Oncol (2004) 1.09
Patterns of chromosomal alterations in metastasizing and nonmetastasizing primary head and neck carcinomas. Cancer Res (1997) 1.09
Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst (1983) 1.08
Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol (2001) 1.07
Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol (1998) 1.07
Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat (2002) 1.07
Uterine tumor resembling ovarian sex-cord tumor--a case report and review of the literature. Virchows Arch (2001) 1.07
Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histol Histopathol (2007) 1.07
In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin. J Natl Cancer Inst (1984) 1.06
Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer (2003) 1.05
Human papilloma virus status and chromosomal imbalances in primary cervical carcinomas and tumour cell lines. Eur J Cancer (2000) 1.05
Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol (2009) 1.04
Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol (2000) 1.03
Chromosomal imbalances in brain metastases of solid tumors. Brain Pathol (2000) 1.03
DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett (2001) 1.03
Distinct regions of allelic imbalance on chromosome 10q22-q26 in squamous cell carcinomas of the lung. Oncogene (1998) 1.02
Chromosome alterations in breast carcinomas: frequent involvement of DNA losses including chromosomes 4q and 21q. Br J Cancer (1998) 1.02
Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch A Pathol Anat Histopathol (1990) 1.01
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol (2008) 1.01
Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol (2000) 1.00
Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol (1992) 1.00
A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma. Int J Gynecol Cancer (2008) 1.00
Proteasome as an emerging therapeutic target in cancer. Curr Pharm Des (2007) 0.99
[Necessity of increasing autopsy frequency following the introduction of DRGs]. Pathologe (2007) 0.99
[The UICC Telepathology Consultation Center. "Second opinion" over the Internet for pathologists]. Pathologe (2001) 0.99
Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. Br J Cancer (2006) 0.97
Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol (1997) 0.97
Personalized cancer medicine and the future of pathology. Virchows Arch (2011) 0.97
Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer (2000) 0.96
ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer. Int J Biol Markers (2004) 0.96
Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur J Cancer (2001) 0.96